FIELD: biotechnology.
SUBSTANCE: this protein comprises the first and the second polypeptide chains, each having two variable domains linked by a linker. This invention also relates to compositions comprising this binding protein. The compositions of the invention are intended for treatment of a disease characterized by excessive vascular growth, edema or abnormal expression or activity of DLL4 and/or VEGF. The invention also relates to binding protein application in the manufacture of a drug for treatment of this disease.
EFFECT: invention allows preparation of compositions for treatment of a disease characterized by excessive vascular growth, edema or abnormal expression, or DLL4 or VEGF activity.
26 cl, 1 dwg, 36 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| DLL4 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2007 |
|
RU2415869C2 |
| IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
| IL-1 ALPHA AND BETA BISPECIFIC IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | 2011 |
|
RU2627171C2 |
| IL-1 BINDING PROTEINS | 2011 |
|
RU2615173C2 |
| NOVEL DUAL-TARGETED PROTEINS SPECIFICALLY BINDING TO DLL4 AND VEGF, AND USE THEREOF | 2014 |
|
RU2648154C2 |
| METHOD OF TREATING CANCER WITH DLL4 ANTAGONIST AND CHEMOTHERAPEUTIC AGENT | 2010 |
|
RU2571220C2 |
| BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2014 |
|
RU2640253C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
